Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes

Published:2019-02-04 Issue:4 Volume:22 Page:336-343
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Cai Xiaoling¹,Shi Lizheng²,Yang Wenjia¹,Gu Shuyan³,Chen Yingyao⁴,Nie Lin⁵,Ji Linong¹

Affiliation:

1. Department of Endocrinology & Metabolism, Peking University People’s Hospital, Beijing, PR China;

2. Department of Global Health Management and Policy, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA;

3. Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou, PR China;

4. School of Public Health, Fudan University, Shanghai, PR China;

5. Department of Endocrinology & Metabolism, Beijing Airport Hospital, Beijing, PR China

Funder

AstraZeneca Ltd

National Key R&D Program of China

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1570220

Reference44 articles.

1. Primacy of the 3B Approach to Control Risk Factors for Cardiovascular Disease in Type 2 Diabetes Patients

2. International Diabetes Federation. IDF Diabetes Atlas, 8th edition. [cited 2018 Jan 10]. Available from: https://www.idf.org/e-library/epidemiology-research/diabetes-atlas.html2017

3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview

4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

5. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

2. Impact of SGLT2 Inhibitors on Renal Function in Type 2 Diabetic Patients with Coronary Artery Disease Undergoing Percutaneous Intervention: A Systematic Review and Meta-Analysis;Current Diabetes Reviews;2024-07-03

3. Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide;Diabetes, Obesity and Metabolism;2024-05-13

4. A systematic review on reporting quality of economic evaluations for negotiated glucose-lowering drugs in China national reimbursement drug list;BMC Health Services Research;2024-05-01

5. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review;BMJ Global Health;2023-11